 The recent 4-year partnership between Pfizer and Beam Therapeutics involves 300 million upfront to speed validation of the technology and an additional 1.05 billion in milestone payments. A recent amended agreement between Verve Therapeutics and Beam Therapeutics is a target swap that will give Beam access to Verves validated GalNAc-lipid nanoparticle-mediated LNP delivery technology. 